Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
by Zacks Equity Research
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
AVEO Reports Positive Results on Leukemia Drug, Shares Up
by Zacks Equity Research
AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
by Zacks Equity Research
Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.
3 Big Pharma Stocks to Add to Your Portfolio This April
by Kinjel Shah
The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Lilly (LLY) Signs New Immunology Deal With Private Biotech
by Zacks Equity Research
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $128.30 in the latest trading session, marking a -0.01% move from the prior day.
Bull of the Day: DexCom (DXCM)
by Kevin Cook
Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator
Alkermes Focuses on Pipeline, Depends on Partners for Funds
by Zacks Equity Research
Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
by Zacks Equity Research
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
by Zacks Equity Research
Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Eli Lilly (LLY) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $123.50 in the latest trading session, marking no change from the prior day.
Allergan Announces FDA Acceptance of Migraine Candidate NDA
by Zacks Equity Research
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's Depression Candidate Fails in Studies, Stock Down
by Zacks Equity Research
Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
by Zacks Equity Research
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
by Zacks Equity Research
J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q4 loss as Tymlos sales gain traction and capture additional market share.